Completed × Observational × Fatigue × Clear all
NCT03098589 2025-03-30

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Celgene

Completed
1,149 enrolled
NCT02921828 2022-07-05

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Celgene

Completed
1,149 enrolled
NCT00477919 2019-05-15

E-MOSAIC Electronic Tool to Monitor Symptoms

Swiss Cancer Institute

Completed
264 enrolled
NCT00956475 2011-08-24

Quality of Life in Younger Leukemia and Lymphoma Survivors

Case Comprehensive Cancer Center

Completed
48 enrolled